![]() ![]() ![]() Atezolizumab in the treatment of metastatic triple-negative breast cancer. doi: 10.1056/NEJMoa2112651.Ģ) Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. doi: 10.1016/S0140-6736(20)32531-9.Īrticles related to the KEYNOTE-522 Clinical Study:ġ) Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J KEYNOTE-522 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. doi: 10.1056/NEJMoa2202809.Ģ) Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. Nonetheless, this advancement offers a positive advance in treatment for those affected.Īrticles related to the KEYNOTE-355 Clinical Study:ġ) Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P KEYNOTE-355 Investigators. ![]() It is important to remember, however, that results may vary significantly, particularly because the diversity of the of the patient group. ![]() KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test. KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Based on these studies, the FDA approved KEYTRUDA for two indications: The KEYNOTE-355 and KEYNOTE-522 clinical trials concluded that Pembrolizumab (brand name KETRUDA) used together with chemotherapy increased the overall survival in patients. Triple Negative Breast Cancer (TNBC) accounts for 15-20% of all breast cancers, and it is usually found in women under 40, who have BRCA1 mutation, or are black. The new recommendation was based on results of the KEYNOTE-522 trial.In honor of breast cancer awareness month, it seems fitting to highlight recent gains related to an aggressive subtype of the disease that has typically been difficult to treat. It is recommended as 200 mg every 3 weeks or 400 mg every 6 weeks dosing, in combination with neoadjuvant chemotherapy followed by adjuvant pembrolizumab after surgery. Vikas: Pembrolizumab is recommended for patients with Stage II or III triple-negative breast cancer. What is the new recommendation about pembrolizumab in patients with triple-negative breast cancer? He discussed key details in the following interview. Praveen Vikas, MD, of the Holden Comprehensive Cancer Center at the University of Iowa in Iowa City, was on the ASCO Evidence Based Medicine Committee that reviewed the updated guidelines. "The statistically significant event-free survival (EFS) results of the KEYNOTE-522 trial constituted a strong signal for an update of the 2021 ASCO guideline recommendation on the role of pembrolizumab in the treatment of high-risk, early-stage TNBC," the authors wrote. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |